Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) – William Blair raised their FY2025 earnings per share estimates for shares of Charles River Laboratories International in a note issued to investors on Thursday, August 7th. William Blair analyst M. Smock now forecasts that the medical research company will earn $10.29 per share for the year, up from their previous estimate of $9.79. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s FY2026 earnings at $10.95 EPS.\n\nSeveral other research firms have also weighed in on CRL. Barclays increased their price target on Charles River Laboratories International from $155.00 to $165.00 and gave the company an \"equal weight\" rating in a report on Thursday. Redburn Atlantic upgraded Charles River Laboratories International from a \"neutral\" rating to a \"buy\" rating and reduced their target price for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a \"neutral\" rating in a research note on Thursday, May 8th. Cowen upgraded Charles River Laboratories International from a \"hold\" rating to a \"buy\" rating in a research note on Wednesday, May 14th. Finally, JPMorgan Chase & Co. increased their target price on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a \"neutral\" rating in a research note on Thursday. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of \"Hold\" and a consensus price target of $175.69.\n\nNYSE:CRL opened at $149.07 on Monday. The stock’s fifty day moving average is $155.55 and its 200 day moving average is $149.11. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $230.02. The firm has a market capitalization of $7.34 billion, a PE ratio of -112.08, a PEG ratio of 4.74 and a beta of 1.48. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36.\n\nCharles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. During the same quarter in the prior year, the firm posted $2.80 EPS. Charles River Laboratories International’s quarterly revenue was up .6% compared to the same quarter last year.\n\nInstitutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. boosted its holdings in Charles River Laboratories International by 5.6% in the fourth quarter. American Century Companies Inc. now owns 2,984 shares of the medical research company’s stock worth $551,000 after acquiring an additional 157 shares in the last quarter. Bank of Nova Scotia boosted its holdings in Charles River Laboratories International by 4.9% in the fourth quarter. Bank of Nova Scotia now owns 5,011 shares of the medical research company’s stock worth $925,000 after acquiring an additional 232 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Charles River Laboratories International in the fourth quarter worth about $42,776,000. F M Investments LLC acquired a new stake in Charles River Laboratories International in the fourth quarter worth about $361,000. Finally, Capital Fund Management S.A. boosted its holdings in Charles River Laboratories International by 13.8% in the fourth quarter. Capital Fund Management S.A. now owns 27,786 shares of the medical research company’s stock worth $5,129,000 after acquiring an additional 3,371 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.\n\nIn related news, EVP Joseph W. Laplume sold 400 shares of the firm’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $150.04, for a total transaction of $60,016.00. Following the sale, the executive vice president owned 24,916 shares of the company’s stock, valued at $3,738,396.64. This trade represents a 1.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 1,040 shares of company stock worth $152,423 over the last 90 days. 1.30% of the stock is owned by company insiders.\n\nCharles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

William Blair Has Optimistic Outlook of CRL FY2025 Earnings

William Blair raised its full-year 2025 earnings per share estimate for Charles River Laboratories International (CRL) from $9.79 to $10.29, with a consensus estimate of $9.36. The firm also forecasted $10.95 EPS for FY2026. Other analysts including Barclays, Redburn Atlantic, Robert W. Baird, Cowen, and JPMorgan Chase & Co. have updated their price targets and ratings on CRL, with some upgrading to 'buy'. The company reported Q2 earnings of $3.12 EPS, exceeding estimates, and recorded revenue of $1.03 billion. Institutional investors increased their holdings in the fourth quarter, with American Century Companies Inc., Bank of Nova Scotia, Raymond James Financial Inc., F M Investments LLC, and Capital Fund Management S.A. acquiring shares. Executive Vice President Joseph W. Laplume sold 400 shares worth $60,016, reducing his ownership by 1.58%. CRL operates globally in drug discovery, non-clinical development, and safety testing across the U.S., Europe, Canada, Asia Pacific, and internationally.